We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Treatment of erythrodermic psoriasis in HCV+ patient with adalimumab.
- Authors
Richetta, Antonio Giovanni; Maiani, Elisa; Carlomagno, Valentina; Carboni, Valentina; Mattozzi, Carlo; Giancristoforo, Simona; Calvieri, Stefano
- Abstract
Erythrodermic psoriasis is a severe and disabling variant of psoriasis. The authors present the case of a 48-year-old man with psoriasis and hemophilia presented with a history of hepatitis C virus (HCV) infection treated with pegylated interferon alpha-2a and ribavirin therapy. At the end of antiviral therapy, skin manifestation progressively worsened, becoming erythrodermic, with lack of efficacy of steroid therapy. The authors decided to start biological therapy with induction dose of adalimumab (Humira, Abbott Laboratories, Abbott Park, Chicago, IL) 80 mg at Week 0 and 40 mg weekly. In our case, this resulted in a highly effective and safe treatment.
- Subjects
CASE studies; PSORIASIS; HEMOPHILIA; SKIN diseases; DRUG administration; THERAPEUTICS
- Publication
Dermatologic Therapy, 2009, Vol 22, pS16
- ISSN
1396-0296
- Publication type
Article
- DOI
10.1111/j.1529-8019.2009.01266.x